PL355431A1 - Środki złożone do leczenia jaskry - Google Patents

Środki złożone do leczenia jaskry

Info

Publication number
PL355431A1
PL355431A1 PL00355431A PL35543100A PL355431A1 PL 355431 A1 PL355431 A1 PL 355431A1 PL 00355431 A PL00355431 A PL 00355431A PL 35543100 A PL35543100 A PL 35543100A PL 355431 A1 PL355431 A1 PL 355431A1
Authority
PL
Poland
Prior art keywords
treating glaucoma
concomitant drugs
active ingredients
glaucoma
prostaglandins
Prior art date
Application number
PL00355431A
Other languages
English (en)
Other versions
PL201783B1 (pl
Inventor
Tomihisa Yokoyama
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Publication of PL355431A1 publication Critical patent/PL355431A1/pl
Publication of PL201783B1 publication Critical patent/PL201783B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL355431A 1999-12-01 2000-12-01 Środek do profilaktyki lub leczenia jaskry zawierający antagonistę angiotensyny II oraz zastosowanie antagonisty angiotensyny II do wytwarzania lekarstwa PL201783B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34152499 1999-12-01
JP2000078769 2000-03-21
PCT/JP2000/008545 WO2001039805A1 (fr) 1999-12-01 2000-12-01 Coprescription pour le traitement du glaucome

Publications (2)

Publication Number Publication Date
PL355431A1 true PL355431A1 (pl) 2004-04-19
PL201783B1 PL201783B1 (pl) 2009-05-29

Family

ID=26576988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL355431A PL201783B1 (pl) 1999-12-01 2000-12-01 Środek do profilaktyki lub leczenia jaskry zawierający antagonistę angiotensyny II oraz zastosowanie antagonisty angiotensyny II do wytwarzania lekarstwa

Country Status (22)

Country Link
US (4) US7307096B2 (pl)
EP (3) EP1234582B1 (pl)
JP (1) JP4000505B2 (pl)
KR (3) KR20040045029A (pl)
CN (3) CN1615880A (pl)
AT (1) ATE332145T1 (pl)
AU (1) AU773110B2 (pl)
BR (1) BR0015980A (pl)
CA (1) CA2392804C (pl)
CZ (1) CZ20021829A3 (pl)
DE (1) DE60029242T2 (pl)
ES (1) ES2267586T3 (pl)
HK (1) HK1047239B (pl)
HU (1) HUP0204049A3 (pl)
IL (2) IL149444A0 (pl)
MX (1) MXPA02005505A (pl)
NO (1) NO20022584L (pl)
NZ (1) NZ518930A (pl)
PL (1) PL201783B1 (pl)
RU (4) RU2002114335A (pl)
TW (1) TWI290470B (pl)
WO (1) WO2001039805A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386611A4 (en) * 2001-04-19 2009-05-13 Teika Pharmaceutical Co Ltd MEDICINES AND MEDICAL KITS
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP5222462B2 (ja) * 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
WO2005079809A1 (ja) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. 澄明なラタノプロスト点眼液
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
KR20130139748A (ko) * 2010-05-07 2013-12-23 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 안과용 조성물
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR101327267B1 (ko) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 엔드이펙터용 구동력 전달장치
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents
CN107106570B (zh) * 2014-12-12 2021-02-05 兴和株式会社 水性组合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS536156B2 (pl) 1972-10-30 1978-03-04
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
EP0189690B1 (en) * 1984-12-12 1989-03-01 Merck & Co. Inc. Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (ja) * 1987-07-22 1997-05-14 エーザイ株式会社 高眼圧症治療用点眼剤
JPS6426518U (pl) 1987-08-11 1989-02-15
EP0364417B9 (en) 1988-09-06 2004-10-06 Pharmacia AB Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
JP3045511B2 (ja) 1988-09-09 2000-05-29 ドレナート、クラウス 人工腰関節およびその使用
EP0375299A1 (en) * 1988-12-19 1990-06-27 Merck & Co. Inc. Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
US5250521A (en) 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
CA2129037C (en) * 1992-02-21 1998-03-24 Thomas Robert Dean Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
WO1995021609A1 (en) * 1994-02-08 1995-08-17 Ciba-Geigy Ag Treatment of normotensive glaucoma with angiotensin ii antagonists
EP1110551B1 (en) * 1994-03-16 2004-05-12 Sankyo Company Limited Ocular tension lowering agent
CA2185524C (en) * 1994-03-16 2006-12-05 Tomihisa Yokoyama Ocular tension depressant
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
RU2188013C2 (ru) * 1996-04-05 2002-08-27 Такеда Кемикал Индастриз, Лтд. Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO1998050024A1 (en) 1997-05-09 1998-11-12 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
CZ300553B6 (cs) * 1999-06-11 2009-06-17 Sankyo Company Limited Místne podávané prostredky ke snížení nitroocního tlaku

Also Published As

Publication number Publication date
PL201783B1 (pl) 2009-05-29
KR20020058034A (ko) 2002-07-12
AU773110B2 (en) 2004-05-20
DE60029242D1 (de) 2006-08-17
JP2001335511A (ja) 2001-12-04
WO2001039805A1 (fr) 2001-06-07
RU2004111359A (ru) 2005-09-20
RU2299067C2 (ru) 2007-05-20
US20050043383A1 (en) 2005-02-24
TWI290470B (en) 2007-12-01
MXPA02005505A (es) 2002-09-02
DE60029242T2 (de) 2007-07-05
IL149444A0 (en) 2002-11-10
CZ20021829A3 (cs) 2002-08-14
CA2392804C (en) 2009-02-03
AU1557501A (en) 2001-06-12
EP1234582B1 (en) 2006-07-05
RU2004111358A (ru) 2005-09-20
CN1407903A (zh) 2003-04-02
NO20022584D0 (no) 2002-05-31
EP1344535A2 (en) 2003-09-17
KR20040045028A (ko) 2004-05-31
EP1344534A3 (en) 2004-01-02
US20080221184A1 (en) 2008-09-11
CN1263512C (zh) 2006-07-12
JP4000505B2 (ja) 2007-10-31
CN1615880A (zh) 2005-05-18
HUP0204049A2 (hu) 2003-04-28
NO20022584L (no) 2002-07-29
KR20040045029A (ko) 2004-05-31
CN1615879A (zh) 2005-05-18
ES2267586T3 (es) 2007-03-16
EP1234582A1 (en) 2002-08-28
RU2004111357A (ru) 2005-09-20
ATE332145T1 (de) 2006-07-15
EP1344534A2 (en) 2003-09-17
EP1234582A4 (en) 2003-05-07
HUP0204049A3 (en) 2006-07-28
US20030040529A1 (en) 2003-02-27
BR0015980A (pt) 2002-11-12
US7307096B2 (en) 2007-12-11
NZ518930A (en) 2003-09-26
RU2002114335A (ru) 2004-01-10
KR100607430B1 (ko) 2006-08-02
EP1344535A3 (en) 2004-01-28
CA2392804A1 (en) 2001-06-07
HK1047239A1 (en) 2003-02-14
HK1047239B (zh) 2006-12-08
IL149444A (en) 2007-06-17
US20050014808A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
HK1047239A1 (en) Concomitant drugs for treating glaucoma
IL162340A (en) Use of selective modulators for androgen receptor for the preparation of a drug for the treatment of muscle depletion
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
EP1108435A4 (en) MEANS FOR PREVENTING OR TREATING PANCREATITIS CONTAINING THE IL-6 ANTAGONISTS AS ACTIVE COMPONENTS
HK1157331A1 (zh) 血小板 受體抑制劑
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
EE200200355A (et) EP4 retseptori selektiivsed agonistid osteoporoosi raviks
MY133564A (en) Compositions and methods for treating osteoporosis and lowering cholesterol
MY133996A (en) Compounds for the treatment of ischemia
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
MXPA01010988A (es) Uso de un compuesto macrolido para el tratamiento del ojo seco.
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
GB9815618D0 (en) Treatment of dyskinesia
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
ID29818A (id) Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
WO2003097086A3 (en) Egf receptor antagonists in the treatment of gastric cancer
DE69731657D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
WO2002078633A3 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
NO20004363L (no) Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20091201